Orexo announces FDA acceptance of Investigational New Drug (IND) application for OX640 for the treatment of anaphylaxis
Orexo AB (publ.) today announces that the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug (IND) application for OX640, a nasally administered powder formulation of epinephrine…